'New opportunities could arise from combining the rapidity, automatability, and consistency of bioprinting with the functional capability and biofidelity of tissue engineering' Read more of Proffesor Costa's article for BioProcess Intl. here: bit.ly/2OxtlSI

In this BPI Elucidation, Kevin Costa of Novoheart explains how human iPSC-derived cardiomyocytes are combining with developments in #bioengineering & #bioprinting to enhance preclinical testing. Learn more about that and about Novoheart's systems here: ow.ly/7HmQ50ykC0L

From our mini-heart to yours, here's an article mentioning Novoheart's ongoing collaboration with @harvard Read it here: bit.ly/2Src1Rt

Novoheart is to enter a billion-dollar market and generate recurring revenue from the sale of its new and proprietary microplates to global pharmaceuticals and biotech clients. Read more: bit.ly/31ufnWV

“Screening capacity and accuracy represent two of the most current and significant issues facing those developing new, innovative and life-saving drugs and treatments,” Novoheart CEO, Ronald Li. Read more: bit.ly/31ufnWV

Very proud to announce Novoheart has been named a 2020 Venture 50 company, ranked among the year's top 10 performing stocks in Life Sciences! ❤️🏆 #TSXVenture50 Canada's Markets

Congratulations Novoheart!

After recognition by the Canada's Markets as a top performing Life Sciences company, CEO Prof. Ron Li discusses the maturing of the 'Human Heart-in-a-jar' technology and growing presence in the field of drug discovery and development #TSXVenture50 #TSX

Novoheart recently partnered with AstraZeneca to create the first ever in vitro model reproducing phenotypic characteristics of heart failure. Read more: bit.ly/2UB0TTP

Novoheart was recognized among a number of great innovators as part of this year's TSX Venture 50. Some inspiring companies to watch in the coming months and years. See the full list of winners here. bit.ly/2TtTeED

Novoheart’s new and proprietary microplates, developed with a global pharma, ecompass 96 individual wells, each able to cultivate a single human ventricular Cardiac Tissue Strip (hvCTS) Read more: bit.ly/31ufnWV

“3D Heart Models Suggest Restoring Frataxin Could Treat Cardiac Dysfunction in Friedreich’s Ataxia” Read more here: bit.ly/2H59A0l

"​Heart failure is a global pandemic with an estimated 64.3 million cases worldwide in 2017, costing over US$100B per year. Read more here about how Novoheart and Astrazeneca are working to create a new tool in the worldwide battle against heart failure: bit.ly/2UB0TTP

Novoheart has received an exclusive license to combine its MyHeart platform with Harvard’s pioneering tissue-engineered scale model of the heart ventricle and bioreactor technology. Read more here: bit.ly/2ufqrLt

Novoheart’s models are set to revolutionize drug testing and overcome the need for animal testing. Find out about Novoheart’s MyHeart™ platform in the latest @fsdrugdiscovery: bit.ly/2QvA68i.

Novoheart’s approach to the discovery and development of new therapeutics marks an important step away from using mice in traditional testing models. Read more here: bit.ly/2ufqrLt

Novoheart has participated in the Safety Pharmacology Society Annual Meeting 2020. At this year’s virtual meeting, we have launched our new CT Screen, which offers drug developers an automated screening tool, using the company’s human ventricular Cardiac Tissue Strip (hvCTS).

We debuted a new commercial platform, the CTScreen, to measure true contractility of 3-D engineered cardiac tissue at #SPSVirtual2020 last week, offering high precision, reliability, and versatility for drug discovery and cardiac research. Find out more: bit.ly/362dsgv

Today is #WorldHeartDay. It’s a day where people from around the world raise awareness of cardiovascular diseases. Let’s use our hearts to spread love and stay healthy!

Our CEO, Professor Ronald Li has a recent interview with South China Morning Post on the exciting news and updates on the company’s business development. scmp.com/business/china…